BOSTON – Researchers from Memorial Sloan-Kettering Cancer Center presented encouraging, though very early, data on Merus NV's bispecific antibody MCLA-128 for the treatment of patients with NRG-1 gene fusions at the AACR-NCI-EORTC Molecular Targets meeting on Sunday.
Two very different roles were reported for the protein REST last week. In adults, REST activation appeared to extend lifespan by reducing overall brain activity. Principal investigator Bruce Yankner, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biology of Aging, told BioWorld MedTech that in postmortem brain samples of individuals who had had no cognitive impairments at the time of their death, his team found "a correlation between down-regulation of excitation and extended longevity."
Two very different roles were reported for the protein REST last week. In adults, REST activation appeared to extend lifespan by reducing overall brain activity. Principal investigator Bruce Yankner, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biology of Aging, told BioWorld that in postmortem brain samples of individuals who had had no cognitive impairments at the time of their death, his team found "a correlation between down-regulation of excitation and extended longevity."
A team at the Broad Institute of Harvard and MIT has developed a genome editing method that could, in principle, correct 90% of the roughly 75,000 currently known genomic changes that are associated with genetic diseases.
A team at the Broad Institute of Harvard and MIT has developed a genome editing method that could, in principle, correct 90% of the roughly 75,000 currently known genomic changes that are associated with genetic diseases.
